The 3 Most Undervalued Biotech Stocks to Buy in February 2024

Core Insights - The article emphasizes the potential for significant wealth creation through investing in undervalued biotech stocks, highlighting examples of companies that have experienced substantial price increases over time [1]. Group 1: Company Highlights - ACADIA Pharmaceuticals (ACAD) saw its stock price rise from $0.70 to a high of $45.10, representing a gain of approximately 6,300% [1]. - CRISPR Therapeutics (CRSP) experienced a surge from around $40 to nearly $77.50 [1]. - Corbus Pharmaceuticals (CRBP) increased from about $5 to nearly $40 following positive Phase 1 trial results for a cancer drug [1]. Group 2: Viking Therapeutics (VKTX) - Viking Therapeutics (VKTX) has risen from approximately $8.50 to a recent high of $24.63 but is still considered undervalued despite positive trial data for its obesity treatment [2]. - The potential for VKTX is underscored by the success of Eli Lilly's obesity drug, Zepbound, which generated $175.8 million in sales in less than a month, exceeding Wall Street's expectations of $75 million [2]. - VKTX's promising Phase 1 study results for VK2735 indicate potential for weight loss, and there is speculation it could be a takeover target [2]. Group 3: ADC Therapeutics (ADCT) - ADC Therapeutics (ADCT) specializes in antibody-drug conjugates (ADCs) and has seen its stock price rise from about $0.50 to $4, yet remains undervalued [3][4]. - ADCs are gaining traction in the biotech sector, as evidenced by Pfizer's $43 billion acquisition of Seagen and interest in acquiring more ADC companies [5]. - ADCT's recent trial results for a combination treatment for relapsed follicular lymphoma showed a 96% overall response rate and an 85% complete response rate, indicating strong potential for future growth [5]. Group 4: Intellia Therapeutics (NTLA) - Intellia Therapeutics (NTLA), a gene editing company, is currently undervalued and has significant upside potential, especially after the success of its competitor, CRISPR Therapeutics [6]. - Cathie Wood's Ark Invest recently acquired 131,000 shares of NTLA, representing 11% of the outstanding shares [6]. - Positive interim Phase 1 data for NTLA-2002, published in The New England Journal of Medicine, suggests that a single dose may eliminate angioedema attacks in patients [6][7]. - NTLA is set to initiate a global pivotal study for NTLA-2002 in the second half of the year, providing solid catalysts for future growth [7].